All News Rezolute, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-24 EDT			5-day change	1st Jan Change
4.26 ^USD	+7.85%		+10.65%	+329.22%

06-14	Rezolute Shares Decline After Company Prices $60 Million Public Offering	MT
06-14	Top Premarket Decliners	MT

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds	06-24	GL
Rezolute Shares Decline After Company Prices $60 Million Public Offering	06-14	MT
Top Premarket Decliners	06-14	MT
Rezolute Prices $60 Million Stock Offering	06-14	MT
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants	06-13	GL
Rezolute Starts Equity Offering -- Shares Fall After Hours	06-13	MT
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	06-13	GL
Rezolute : Corporate Presentation – June 2024	06-10	PU
Sector Update: Health Care Stocks Advance Late Afternoon	06-05	MT
Sector Update: Health Care	06-05	MT
Top Midday Gainers	06-05	MT
Craig-Hallum Initiates Rezolute at Buy Rating With $14 Price Target	06-04	MT
Rezolute to Participate in the Jefferies Global Healthcare Conference	05-30	GL
Traders Cautious Ahead of Fed Minutes, Nvidia Earnings, Stifling US Equity Futures Pre-Bell	05-22	MT
Top Premarket Gainers	05-22	MT
Rezolute : Corporate Presentation – May 2024	05-21	PU
Transcript : Rezolute, Inc. - Special Call	05-21
Rezolute Reports Positive Topline Results in Study of Diabetic Macular Edema Treatment; Shares Surge After Hours	05-21	MT
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)	05-21	GL
Rezolute, Inc. Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema	05-21	CI

No results for this search